Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Head and Neck Cancer Most head and neck cancers (73% in the United States) are now
related to human papillomavirus infection rather than tobacco and alcohol. Primary cancers …

PURPOSE Modulation of vascular endothelial growth factor–mediated immune suppression
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …

Purpose: To construct an immune-related gene prognostic index (IRGPI) for head and neck
squamous cell carcinoma (HNSCC) and clarify the molecular and immune characteristics …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

The use of immune checkpoint inhibitors (ICIs) has become one of the most promising
approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells …

The aim of this review is to summarize current available information about the role of
PI3K/AKT/mTOR signaling in head and neck cancer as a potential target for new therapy …

Immunotherapy has dramatically changed the treatment landscape for patients with cancer.
Programmed death–ligand 1/programmed death‐1 checkpoint inhibitors have been in the …

Expression of programmed cell death-ligand 1 (PD-L1) is being used as predictive
biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC) …

PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-
PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD …